Screener
Ginkgo Bioworks DNA Preferred Stock, Shares Authorized
Preferred Stock, Shares Authorized at other companies
Other financials
Where this comes from
Reported directly by Ginkgo Bioworks in its filing.
Tagged under the XBRL concept us-gaap:PreferredStockSharesAuthorized.
The source filing: Ginkgo Bioworks’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:09 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-054298
| Line item | As of June 30, 2026 | As of December 31, 2025 |
|---|---|---|
| Total liabilities | 569,762 | 611,106 |
| Commitments and contingencies (Note 10) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value; 200,000,000 shares authorized; none issued | — | — |
| Common stock, $0.0001 par value (Note 8) | 6 | 6 |
| Additional paid-in capital | 6,698,945 | 6,657,053 |
| Accumulated deficit | (6,279,617) | (6,150,320) |
| Accumulated other comprehensive income | 950 | 1,851 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Ginkgo Bioworks's preferred stock, shares authorized?
- Ginkgo Bioworks (DNA) reported preferred stock, shares authorized of $200M in Q2 2026.
- How has Ginkgo Bioworks's preferred stock, shares authorized changed year-over-year?
- Ginkgo Bioworks's preferred stock, shares authorized decreased by 0.0% year-over-year, from $200M to $200M.
- What is the long-term trend for Ginkgo Bioworks's preferred stock, shares authorized?
- Over 5 years (2020 to 2025), Ginkgo Bioworks's preferred stock, shares authorized has grown at a 0.0% compound annual growth rate (CAGR), from $200M to $200M.
- What does preferred stock, shares authorized mean?
- Preferred Stock, Shares Authorized
Ask your AI about Ginkgo Bioworks's preferred stock, shares authorized.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude